Par Pharmaceutical Resumes Generic Flonase Sales
Par Pharmaceutical(PRX Quote) announced Tuesday that it resumed shipment of fluticasone propionate nasal spray, a substitute for GlaxoSmithKline's >(GSK Quote) Flonase.
Par had stopped all shipments since Feb. 23 after a temporary restraining order was granted to GSK by the U.S. District Court for the District of Maryland. On Monday evening, the court denied GlaxoSmithKline's motion to set aside the Food and Drug Administration's approval of the generic spray, and the restraining order was allowed to expire. Annual sales of Flonase in the U.S. exceed $900 million. Shares of Par Pharmaceutical rose 32 cents, or 1.1%, to $28.99 Tuesday.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
-
Honda issues global airbag recall
BBC
-
Ore Increases Boost Steel Prices
The Wall Street Journal.
-
Europe Weighs Rescue Plan for Greece
WSJ.com: Asia Home
-
Paulson Tells Buffett Banks to Repay ‘Every Penny’ (Update2)
BusinessWeek Online
-
U.S. Stocks Rally on Growing Prospects for Bailout of Greece
BusinessWeek Online
-
Clive Palmer Clarifies His $60B China Coal Sale
Forbes.com: Business News
-
Why fret about Greece?
The Economist
-
China Passes Germany as Worlds Top Exporter
New York Times
-
IAC Posts Loss, but Still Beats Expectations
New York Times
-
Tuesday Reads
The Big Picture
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,058.64 | 1,070.52 | 2,150.87 | 36.33 |
Oil *
72.02
|
|
UP
150.25
|
UP
13.78
|
UP
24.82
|
UP
0.41
|
10 Yr
3.63%
SPDR Gold
105.45
|
|
+1.52%
|
+1.30%
|
+1.17%
|
+1.14%
|
Data delayed 20 minutes |
More From TheStreet
Latest Headlines
Brokerage Partners
Sponsored Links
